25 - Pneumococcal conjugate vaccine and pneumococcal common protein vaccines
References (0)
Cited by (23)
Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study
2023, VaccineCitation Excerpt :The PCV13 vaccine was developed in 2010 and approved for marketing in the United States [9]. Initially applied in children, the vaccine has been reported to have a high efficacy in reducing incidence and mortality from pneumococcal disease [10], a long duration of immunity, and herd protection by affecting nasopharyngeal colonization of pneumococcus [9]. In 2011, the license of PCV13 was extended to include prevention of IPD in adults aged 50 years and older [11].
Parents’ concerns about vaccine scheduling in Shanghai, China
2017, VaccineCitation Excerpt :Co-administration of vaccines limits the number of clinic visits while also inducing immunity against vaccine-preventable diseases at an early age [2]. Decades of research have shown that vaccines are highly safe [3], and concurrent administration has a minimal impact on safety [4] or effectiveness of the separate vaccine components [5]. Many parents, politicians, and others have expressed concerns and hesitancy surrounding vaccination, especially towards the perceived “crowding” of the vaccination schedule [6,7].
Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration
2016, VaccineCitation Excerpt :Nasopharyngeal (NP) colonization is a prerequisite for the development of pneumococcal disease and is responsible for transmission of pneumococci to other individuals. Importantly, NP colonization of pneumococci of serotypes included in the pneumococcal conjugate vaccines (PCVs) is reduced after vaccination with PCVs by preventing NP acquisition [2–5]. Studies suggested that there is an association between increasing serum antipolysaccharide immunoglobulin G (IgG) concentrations after PCV vaccination and decreasing probability of acquisition for some vaccine serotypes [4,6].
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults
2015, VaccineCitation Excerpt :Also, individuals living in crowded, closed settings and patients with certain chronic conditions are at increased risk of developing pneumococcal infection and severe pneumococcal illness. Among children ≥2 years of age and young adults, those with a wide variety of diseases, such as heart disease, chronic lung disease, sickle-cell anemia, Hodgkin disease, congenital or acquired immunodeficiency, diabetes mellitus, nephrotic syndrome, as well as those with functional or anatomic asplenia, are at increased risk of developing IPD in comparison to healthy individuals [7–13]. Vaccination represents an important public health tool that can be used to reduce disease caused by vaccine strains.
Understanding the host-pathogen interaction saves lives: Lessons from vaccines and vaccinations
2015, Current Opinion in ImmunologyCitation Excerpt :The ability of a vaccine to not only induce protection against disease but also to induce protection against infection and spread of the pathogen plays a critical role in achievement of herd immunity and subsequent reduction of transmission in the community, important policy considerations. Pneumococcal conjugate vaccine has had a marked impact on vaccine serotype-specific nasopharyngeal carriage thus preventing transmission of vaccine type causes of disease [10,11]. Oral polio vaccine (OPV) is able to induce actual community immunity through passive spread of vaccine virus [12].